Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 23

  • 369 clinical trials
  • 123 recruiting
  • 134 conditions
  • 27 countries

Conditions in this area

134 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome29Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Rhinitis allergic16Dry age-related macular degeneration15Diabetic retinal oedema13Dry eye12Retinitis pigmentosa11Age-related macular degeneration10Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Rheumatoid arthritis6+110

Clinical trials in Eye disorders

369 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

369 clinical trials

Arteriosclerosis+2

Not recruiting

Long-term Safety Study of INZ-701 for Patients with ENPP1 and ABCC6 Deficiencies, Including Pseudoxanthoma Elasticum and Generalized Arterial Calcification of Infancy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Choroid melanoma

Not recruiting

Preventing Neovascular Glaucoma in Patients with Large Choroidal Melanoma Using Aflibercept During Proton Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Centre Hospitalier Universitaire De Nice

Choroidal dystrophy+1

Not recruiting

Long-term Safety and Efficacy Study of Gene Therapy for Choroideremia and X-Linked Retinitis Pigmentosa Using AAV2-REP1 and AAV8-RPGR in Previously Treated Patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Timrepigene Emparvovec
  • Sponsor:Biogen Idec Research Limited

Corneal dystrophy

Not recruiting

Study on the Effectiveness and Safety of STN1010904 Eye Drops for Patients with Fuchs Endothelial Corneal Dystrophy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sirolimus
  • Sponsor:Santen Inc.

Retinopathy of prematurity

Not recruiting

Long-Term Study on Aflibercept for Retinopathy of Prematurity in Children

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Aflibercept
  • Sponsor:Regeneron Pharmaceuticals Inc.

Sjogren's syndrome

Not recruiting

Study on the Effectiveness of Human Normal Immunoglobulin for Treating Painful Nerve Damage in Patients with Primary Sjögren's Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Optic ischaemic neuropathy

Not recruiting

Study on the Effects of Bosentan for Patients with Early Stage Non-Arteritic Anterior Ischemic Optic Neuropathy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosentan
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Myopia

Not recruiting

Study on the Effects of Atropine Sulfate Monohydrate Eye Drops in Slowing Myopia Progression in Children

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Atropine Sulfate Monohydrate
  • Sponsor:Fakultni Nemocnice Brno

Sjogren's syndrome

Not recruiting

Study on Anifrolumab for Patients with Primary Sjogren's Syndrome

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Universitair Medisch Centrum Groningen

Optic glioma

Not recruiting

Study on the Safety and Effectiveness of Nerve Growth Factor CHF6467 for Children and Young Adults with Optic Pathway Glioma

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Nerve Growth Factor, Recombinant (R100E)
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Exudative retinopathy

Not recruiting

Study on Bevacizumab Injections for Patients with Coats' Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Bevacizumab
  • Sponsor:Fondation A De Rothschild

Retinal vein occlusion

Not recruiting

Study on the Effect of Aflibercept Injections in Patients with Central Retinal Vein Occlusion (CRVO) and Spontaneous Retinal Arterial Pulsations (SRAPs)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Fondation A De Rothschild

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.